The role of epigenetics in age-related macular degeneration – (Eye 28, 1407 (December 2014))
The role of epigenetics in age-related macular degeneration Eye 28, 1407 (December 2014). doi:10.1038/eye.2014.225 Authors: M Gemenetzi & A J Lotery
Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review – (Eye 28, 1399 (December 2014))
Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review Eye 28, 1399 (December 2014). doi:10.1038/eye.2014.214 Authors: M M Castillo, G Mowatt, N Lois, A Elders, C Fraser, W Amoaku, J M Burr, A J Lotery, C R Ramsay & A Azuara-Blanco
RCOphth calls for review of Avastin for use in AMD treatment
Professor Carrie MacEwen and Professor Andrew Lotery co-author the editorial ‘What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?’, published online on BMJ, calls for UK regulatory bodies to review and appraise use of bevacizumab for use in AMD treatment. Ranibizumab (Lucentis), the first drug used to treat this
Survey finds nearly 70% of patients waiting too long for treatment
A survey of ophthalmologists found that nearly 70% of patients with wet age-related macular degeneration (AMD) had to wait more than the recommended two weeks for their first sight-saving injection. Many also wait too long for follow up treatment. The Royal College of Ophthalmologists and the Macular Society say their research shows that more resources
President’s foreword for RNIB Report ‘Real Patients Coming to Real Harm’ Wales
A substantial part of the workload of ophthalmology services is the care of long term conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration. These conditions all become increasingly common with advancing age and all require timely recognition and treatment in order to avoid preventable sight loss. Unfortunately, clinical services for these long-term conditions